Name: Dersimelagon (MT-7117) in Erythropoietic protoporphyria or X-linked protoporphyria: Indication
Published: 2026-09-21T21:42:40-04:00

Product information and disease description Product description Product information

Indication

4 evidence topics · 5 sources

Indication stated in the United States filing announcement

“the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for an investigational oral selective melanocortin 1 receptor (MC1R) agonist, MT-7117 (dersimelagon), for the treatment of erythropoietic protoporphyria (EPP) and X-Linked Protoporphyria (XLP).” (opens the source at this quote in a new tab)

Indication wording in the rights transfer announcement

“for the indication of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) with a history of photosensitivity (including severe pain caused by sunlight exposure)” (opens the source at this quote in a new tab)

Age range of the population studied in the phase 3 trial

“After screening, study participants (ranging from 12 to 75 years of age) received either dersimelagon 200 mg or placebo once daily.” (opens the source at this quote in a new tab)

Intended use and age scope recorded in European sources

“Intended use” (opens the source at this quote in a new tab)
“Treatment of erythropoietic protoporphyria” (opens the source at this quote in a new tab)

“Dersimelagon monotherapy for treatment of X-linked or erythropoietic protoporphyria in adolescents, adults and elderly.” (opens the source at this quote in a new tab)